Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study.

<h4>Background</h4>The majority of people with hypertension require more than one medication to achieve blood pressure control. Many patients are prescribed multipill antihypertensive regimens rather than single-pill fixed-dose combination (FDC) treatment. Although FDC use may improve me...

Full description

Saved in:
Bibliographic Details
Main Authors: Amol A Verma, Wayne Khuu, Mina Tadrous, Tara Gomes, Muhammad M Mamdani
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-06-01
Series:PLoS Medicine
Online Access:https://storage.googleapis.com/plos-corpus-prod/10.1371/journal.pmed.1002584/1/pmed.1002584.pdf?X-Goog-Algorithm=GOOG4-RSA-SHA256&X-Goog-Credential=wombat-sa%40plos-prod.iam.gserviceaccount.com%2F20210219%2Fauto%2Fstorage%2Fgoog4_request&X-Goog-Date=20210219T065342Z&X-Goog-Expires=3600&X-Goog-SignedHeaders=host&X-Goog-Signature=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
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849722196934524928
author Amol A Verma
Wayne Khuu
Mina Tadrous
Tara Gomes
Muhammad M Mamdani
author_facet Amol A Verma
Wayne Khuu
Mina Tadrous
Tara Gomes
Muhammad M Mamdani
author_sort Amol A Verma
collection DOAJ
description <h4>Background</h4>The majority of people with hypertension require more than one medication to achieve blood pressure control. Many patients are prescribed multipill antihypertensive regimens rather than single-pill fixed-dose combination (FDC) treatment. Although FDC use may improve medication adherence, the impact on patient outcomes is unclear. We compared clinical outcomes and medication adherence with FDC therapy versus multipill combination therapy in a real-world setting using linked clinical and administrative databases.<h4>Methods and findings</h4>We conducted a population-based retrospective cohort study of 13,350 individuals 66 years and older in Ontario, Canada with up to 5 years of follow-up. We included individuals who were newly initiated on one angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II-receptor blocker (ARB) plus one thiazide diuretic. High-dimensional propensity score matching was used to compare individuals receiving FDC versus multipill therapy. The primary outcome was a composite of death or hospitalization for acute myocardial infarction (AMI), heart failure, or stroke. We conducted 2 analyses to examine the association between adherence and patient outcomes. First, we performed an on-treatment analysis to determine whether outcomes differed between groups while patients were on treatment, censoring patients when they first discontinued treatment, defined as not receiving medications within 150% of the previous days' supply. Second, we conducted an intention-to-treat analysis that followed individuals allowing for breaks in treatment to quantify the difference in drug adherence between groups and assess its impact on clinical outcomes. As expected, there was no significant difference in the primary outcome between groups in the on-treatment analysis (HR 1.06, 95% CI 0.86-1.31, P = 0.60). In the intention-to-treat analysis, the proportion of total follow-up days covered with medications was significantly greater in the FDC group (70%; IQR 19-98) than in the multipill group (42%, IQR 11-91, P < 0.01), and the primary outcome was less frequent in FDC recipients (3.4 versus 3.9 events per 100 person-years; HR 0.89, 95% CI 0.81-0.97, P < 0.01). The main limitations of this study were the lack of data regarding cause of death and blood pressure measurements and the possibility of residual confounding.<h4>Conclusions</h4>Among older adults initiating combination antihypertensive treatment, FDC therapy was associated with a significantly lower risk of composite clinical outcomes, which may be related to better medication adherence.
format Article
id doaj-art-b703daaafce741e09ba9e72860a77ee7
institution DOAJ
issn 1549-1277
1549-1676
language English
publishDate 2018-06-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Medicine
spelling doaj-art-b703daaafce741e09ba9e72860a77ee72025-08-20T03:11:25ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762018-06-01156e100258410.1371/journal.pmed.1002584Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study.Amol A VermaWayne KhuuMina TadrousTara GomesMuhammad M Mamdani<h4>Background</h4>The majority of people with hypertension require more than one medication to achieve blood pressure control. Many patients are prescribed multipill antihypertensive regimens rather than single-pill fixed-dose combination (FDC) treatment. Although FDC use may improve medication adherence, the impact on patient outcomes is unclear. We compared clinical outcomes and medication adherence with FDC therapy versus multipill combination therapy in a real-world setting using linked clinical and administrative databases.<h4>Methods and findings</h4>We conducted a population-based retrospective cohort study of 13,350 individuals 66 years and older in Ontario, Canada with up to 5 years of follow-up. We included individuals who were newly initiated on one angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II-receptor blocker (ARB) plus one thiazide diuretic. High-dimensional propensity score matching was used to compare individuals receiving FDC versus multipill therapy. The primary outcome was a composite of death or hospitalization for acute myocardial infarction (AMI), heart failure, or stroke. We conducted 2 analyses to examine the association between adherence and patient outcomes. First, we performed an on-treatment analysis to determine whether outcomes differed between groups while patients were on treatment, censoring patients when they first discontinued treatment, defined as not receiving medications within 150% of the previous days' supply. Second, we conducted an intention-to-treat analysis that followed individuals allowing for breaks in treatment to quantify the difference in drug adherence between groups and assess its impact on clinical outcomes. As expected, there was no significant difference in the primary outcome between groups in the on-treatment analysis (HR 1.06, 95% CI 0.86-1.31, P = 0.60). In the intention-to-treat analysis, the proportion of total follow-up days covered with medications was significantly greater in the FDC group (70%; IQR 19-98) than in the multipill group (42%, IQR 11-91, P < 0.01), and the primary outcome was less frequent in FDC recipients (3.4 versus 3.9 events per 100 person-years; HR 0.89, 95% CI 0.81-0.97, P < 0.01). The main limitations of this study were the lack of data regarding cause of death and blood pressure measurements and the possibility of residual confounding.<h4>Conclusions</h4>Among older adults initiating combination antihypertensive treatment, FDC therapy was associated with a significantly lower risk of composite clinical outcomes, which may be related to better medication adherence.https://storage.googleapis.com/plos-corpus-prod/10.1371/journal.pmed.1002584/1/pmed.1002584.pdf?X-Goog-Algorithm=GOOG4-RSA-SHA256&X-Goog-Credential=wombat-sa%40plos-prod.iam.gserviceaccount.com%2F20210219%2Fauto%2Fstorage%2Fgoog4_request&X-Goog-Date=20210219T065342Z&X-Goog-Expires=3600&X-Goog-SignedHeaders=host&X-Goog-Signature=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
spellingShingle Amol A Verma
Wayne Khuu
Mina Tadrous
Tara Gomes
Muhammad M Mamdani
Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study.
PLoS Medicine
title Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study.
title_full Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study.
title_fullStr Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study.
title_full_unstemmed Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study.
title_short Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study.
title_sort fixed dose combination antihypertensive medications adherence and clinical outcomes a population based retrospective cohort study
url https://storage.googleapis.com/plos-corpus-prod/10.1371/journal.pmed.1002584/1/pmed.1002584.pdf?X-Goog-Algorithm=GOOG4-RSA-SHA256&X-Goog-Credential=wombat-sa%40plos-prod.iam.gserviceaccount.com%2F20210219%2Fauto%2Fstorage%2Fgoog4_request&X-Goog-Date=20210219T065342Z&X-Goog-Expires=3600&X-Goog-SignedHeaders=host&X-Goog-Signature=87fbb5ec9af0d0c74bcf75897b916be146dedf8fc781687864d40eac6316e4d3c1e820510d18c44f12a01a20f54599ba515d9e500dec661789b1eea2f92673b37a72c448a378c4a87d1a5b9d1b5262da01520d9f17ec5f864813f29d4936a269d07ee22c9f691e4da4a42b21c3357cfdc6927b97f1c54db2afe52a39456540da561d82ccbfb633c36209bd0343982995757027f219363fe608da81141fdc8901d71f692036a0d7b9ea36103f8047a3e56a4b75288d12c263db205ee496edb9c9eca528bb159bc1a31835f6a6ef2a4246c8c5ae63527ca7e7d0fddf238b08928579891fa8eb55104142da5931f2e7a437f7738aa878d7249ac1704a31c9272d92
work_keys_str_mv AT amolaverma fixeddosecombinationantihypertensivemedicationsadherenceandclinicaloutcomesapopulationbasedretrospectivecohortstudy
AT waynekhuu fixeddosecombinationantihypertensivemedicationsadherenceandclinicaloutcomesapopulationbasedretrospectivecohortstudy
AT minatadrous fixeddosecombinationantihypertensivemedicationsadherenceandclinicaloutcomesapopulationbasedretrospectivecohortstudy
AT taragomes fixeddosecombinationantihypertensivemedicationsadherenceandclinicaloutcomesapopulationbasedretrospectivecohortstudy
AT muhammadmmamdani fixeddosecombinationantihypertensivemedicationsadherenceandclinicaloutcomesapopulationbasedretrospectivecohortstudy